Five-Year Cycle of Basal Cell Carcinoma Management Re-audit

Stafanous, Sabah N

doi:10.1080/01676830903120799

Cited by 10 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 More recently in the UK, 1 recurrence of malignant eyelid tumour was seen after 5 years, out of 112 patients treated with MMS. 12 For recurrent BCCs managed with MMS locally, the Kaplan-Meier estimate for the 2-year recurrence rate is 2.3%. A 5-year estimate cannot be given because of the limitations of the recorded dataset in earlier versions of the database.…”

Section: Recurrence Ratesmentioning

confidence: 99%

“…9 Most patients with histologically clear tumours plus satisfactory aesthetic and functional outcomes could be safely discharged to their general practitioner, but some follow-up would be required if disease recurrence rates are to be established in the UK. 12 In practice, to circumvent difficulties in achieving this for all patients, a sufficiently sized sample group of patients or centres could be randomly selected.…”

Section: Recurrence Ratesmentioning

confidence: 99%

See 1 more Smart Citation

Seven years' experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards

MacFarlane

Waters

Evans

et al. 2013

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

SummaryBackground. Mohs micrographic surgery (MMS) is the gold-standard treatment for high-risk basal cell carcinomas and a variety of other cutaneous tumours, including dermatofibromasarcoma protuberans and microcystic adnexal carcinoma. Previous large-scale case series, audits and reviews have allowed evaluation of MMS outcomes, such as BCC recurrence rates. However, to date there has been no systematic UK MMS audit, and certain important aspects of care, such as postoperative functional outcomes, have not yet been subject to scrutiny. Aims. To review audit data from our centre, and from this to develop a minimum dataset and audit standards for UK MMS centres, on behalf of the British Society of Dermatological Surgery (BSDS).Methods. An MMS database was developed locally and modified in response to repeated audit cycles since the introduction of the MMS service. A minimum dataset was developed using this experience. Results. In our department, primary BCC recurrence rates are reassuringly low at 0.3%, at both 2 and 5 years. Histopathological discordance is < 2%, and aesthetic and functional outcomes at 3 months are good. Conclusions. The collation of audit data has been simplified by use of the minimum dataset, which we propose for all UK MMS centres, on behalf of the BSDS.

show abstract

Section: Recurrence Ratesmentioning

confidence: 99%

Section: Recurrence Ratesmentioning

confidence: 99%

Seven years' experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards

MacFarlane

Waters

Evans

et al. 2013

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…[32][33][34][35][36][37] In this study, recurrence for pBCC is very uncommon once the excision is histologically complete. 16,38 Our single case of recurrence of pBCC in 6 years of study was in a case of morpheaform BCC in the medial canthus, which required more than one excision. We therefore propose that those with pBCC with non-aggressive (nodular) histology could be discharged after one 6-monthly follow-up, once complete excision is confirmed, but advised to monitor for new lesions elsewhere.…”

Section: Eyementioning

confidence: 99%

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

Brown

Bamford

et al. 2012

Eye

View full text Add to dashboard Cite

In all, 67% were nodular BCC and 45.4% located in the lower eyelid. The main outcome measure was the recurrence rate. None of the patients with primary nodular BCC suffered recurrence. The recurrence rate for primary morphoeaform BCC following complete excision is 3.8%. In total, 8.1% of patients had several lesions simultaneously whereas 7.8% patients had BCC in multiple locations subsequently (metachronous). Three patients who had previously recurrent BCC (rBCC) treated elsewhere or not using this method had orbital/lacrimal drainage system involvement requiring exenteration. Conclusion We recommend that patients with a single, completely excised primary solid or nodular BCC can be discharged after one 6-monthly review, although they should be instructed to monitor for the development of further lesions. The incidence of recurrence for primary morphoeaform BCC is 3.8% and for rBCC is 3.6% over 5 years and these patients should stay under review for this period.

show abstract

“…Frequent recurrence is one of the most common problems in treatment of BCC patients. Most often, recurrence develops in 0.5-3 year period after the end of treatment [15,16].…”

Section: Basal Cell Carcinoma (Bcc) Is the Most Common Malignant Tumor Inmentioning

confidence: 99%

Head and Neck Basal Cell Carcinoma Treatment. Summary of the Doctoral Thesis

Aleksandrs

View full text Add to dashboard Cite

Analysis of available literature, development of research design and coordination in the Ethics Committee of RSU, selection of patient medical documentation, systematisation of medical data with respect to chosen criteria, patient's routine health analysis, research summary, development of practical recommendations, writing of articles and Doctoral thesis. Research amount and structureResearch is written in Latvian. It consists of following parts: introduction, literature review, methods and materials, results, discussion, conclusions and used literature sources. Research consists of 138 pages. There are 39 tables, 13 figures and 5 Appendices. There are 235 headings in the footnotes. METHODS AND MATERIALS Research type, permission of Ethics CommitteeResearch typeretrospective. Research is accepted by Rīga Stradinš University Ethics Committee decision on 23 September 2010. Research structureResearch consists of 2 parts: 1 partefficacy analysis of different head and neck basal cell carcinoma treatment methods, taking into account development of recurrence (observation performed more than 5 years after the treatment) (futher in the text -recurrence analysis‖); 2 partefficacy analysis of head and neck basal cell carcinoma treatment methods, taking into account the cosmetic results (futher in the text -scar analysis‖), if during more than 5 year follow up period there was no recurrence.

show abstract

Five-Year Cycle of Basal Cell Carcinoma Management Re-audit

Cited by 10 publications

References 6 publications

Seven years' experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards

Seven years' experience of Mohs micrographic surgery in a UK centre, and development of a UK minimum dataset and audit standards

5 Years review of periocular basal cell carcinoma and proposed follow-up protocol

Head and Neck Basal Cell Carcinoma Treatment. Summary of the Doctoral Thesis

Contact Info

Product

Resources

About